Assessment of Lung Function (Lufu) at Sea Level LA vs. High Altitude HA in Patients With Pulmonary Arterial Hypertension PAH

ConditionsPulmonary Arterial Hypertension (PAH)Pulmonary Vascular Disease High Altitude Effects High Altitude Lung Function Testing Lung Function Changes

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-80

SponsorSilvia Ulrich Somaini

About this trial

To study the effect of a re-ascent to high altitude (Quito Ecuador: 2850m) after a one-week stay at sea level (after prior descent from 2850m) on lung function and pulmonary resistance/reactance in patients with pulmonary arterial disease PAH, who live permanently \> 2600m.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients aged 18-80 years and of all genders

Permanent residence > 2600 m

Diagnosis of pulmonary arterial hypertension PAH (PAHHA-Group) according to guidelines

Patients are stable on therapy

Disqualifiers

Age <18 years or >80 years

unstable condition

Patients who cannot follow the study investigations

Patient permanently living < 2600m.

Trial design

Design model

Single group

Treatments tested in this trial

Re-ascent from sea level to 2850m
Behavioral
Descent from 2850m to sea level with a stay for 7 days and re-ascent/return back to their usual living altitude at 2850m

Treatment groups

20 Participants

are divided into 1 treatment group

Group A: Lung function at sea level and at 2850mExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

FEV1 after re-ascent to 2850m

Difference/change in forced expiratory volume in one second FEV1 between sea level (measurement on the 4th day) and day after re-ascent to 2850m in patients with pulmonary arterial hypertension

Time frame